AVXL Stock Price, Anavex Life Sciences Quote, Chart

Market Summary

USD4.55+0.05

Delayed

1.11%

AVXL Stock Price

View Fullscreen

AVXL RSI Chart

AVXL Valuation

Market Cap

385.1M

Price/Earnings (Trailing)

-9.49

Price/Sales (Trailing)

15.65

EV/EBITDA

-7.47

Price/Free Cashflow

-11.86

AVXL Price/Sales (Trailing)

AVXL Profitability

EBT Margin

-192.65%

Return on Equity

-30.08%

Return on Assets

-28.09%

Free Cashflow Yield

-8.43%

AVXL Fundamentals

AVXL Revenue

Revenue (TTM)

21.0M

Rev. Growth (Yr)

-37.07%

Rev. Growth (Qtr)

-16.41%

AVXL Earnings

Earnings (TTM)

-40.6M

Earnings Growth (Yr)

19.54%

Earnings Growth (Qtr)

-22.32%

Breaking Down AVXL Revenue

Last 7 days

19.4%

Last 30 days

11.8%

Last 90 days

-19.7%

Trailing 12 Months

-51.0%

How does AVXL drawdown profile look like?

AVXL Financial Health

Current Ratio

3.33

Debt/Equity

3e-6

Debt/Cashflow

-94.1K

AVXL Investor Care

Shares Dilution (1Y)

4.71%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	0	0	21.0M	0
2021	31.6M	55.3M	79.1M	50.0M
2020	3.0M	3.7M	7.5M	7.8M
2019	2.8M	1.7M	2.5M	3.0M
2018	0	3.7M	1.6M	2.0M
2017	1.1M	1.5M	2.0M	0
2016	781.4K	758.1K	571.1K	0
2015	0	0	0	776.9K
2013	131.3K	129.2K	176.3K	182.6K
2012	165.4K	150.6K	142.9K	139.2K
2011	91.1K	124.7K	158.2K	180.0K
2010	0	0	24.1K	57.6K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Anavex Life Sciences Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	missling christopher u	acquired	96,861	1.32	73,380	president and ceo
Mar 28, 2024	missling christopher u	sold	-374,972	5.11	-73,380	president and ceo
Jun 29, 2023	missling christopher u	acquired	371,200	1.6	232,000	president and ceo
Jun 28, 2023	missling christopher u	acquired	428,800	1.6	268,000	president and ceo
Jun 28, 2023	missling christopher u	sold	-2,139,310	7.9825	-268,000	president and ceo
May 25, 2022	skarpelos athanasios	sold	-453,000	9.06	-50,000	-
May 25, 2022	skarpelos athanasios	acquired	46,000	0.92	50,000	-
Jun 29, 2021	boenisch sandra	acquired	699,163	4.19424	166,696	pfo and treasurer
Jun 29, 2021	boenisch sandra	sold	-4,422,440	26.53	-166,696	pfo and treasurer
Jun 29, 2021	missling christopher u	sold	-1,342,120	26.00	-51,620	president and ceo

Which funds bought or sold AVXL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-4.52	-377,724	412,555	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-60.02	-817,065	228,541	-%
May 16, 2024	Beacon Capital Management, LLC	reduced	-33.73	-527	560	-%
May 16, 2024	COMERICA BANK	new	-	570	570	-%
May 15, 2024	D. E. Shaw & Co., Inc.	added	30.24	-143,301	354,356	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-93.00	-95,239	3,792	-%
May 15, 2024	SHERBROOKE PARK ADVISERS LLC	new	-	309,538	309,538	0.06%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	1.86	-210,000	264,000	-%
May 15, 2024	OLIVER LAGORE VANVALIN INVESTMENT GROUP	unchanged	-	-3,157	3,807	-%
May 15, 2024	UBS ASSET MANAGEMENT AMERICAS LLC	unchanged	-	-409,020	493,342	-%

Are Funds Buying or Selling AVXL?

Are funds buying AVXL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AVXL

No. of Funds

Unveiling Anavex Life Sciences Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.31%	4,360,648	SC 13G/A
Jan 25, 2024	blackrock inc.	8.1%	6,671,075	SC 13G/A
Jan 22, 2024	state street corp	4.44%	3,642,702	SC 13G/A
Feb 09, 2023	vanguard group inc	5.32%	4,144,500	SC 13G/A
Feb 09, 2023	state street corp	7.46%	5,812,605	SC 13G/A
Jan 31, 2023	blackrock inc.	7.2%	5,578,159	SC 13G/A
Feb 09, 2022	state street corp	5.04%	3,834,034	SC 13G
Feb 09, 2022	vanguard group inc	5.05%	3,841,570	SC 13G
Feb 03, 2022	blackrock inc.	6.9%	5,262,666	SC 13G/A
Feb 16, 2021	park west asset management llc	0.0%	0	SC 13G/A

Recent SEC filings of Anavex Life Sciences Corp

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
May 06, 2024	DEFA14A	DEFA14A
May 06, 2024	DEF 14A	DEF 14A
Apr 01, 2024	4	Insider Trading
Mar 28, 2024	144	Notice of Insider Sale Intent
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading

Peers (Alternatives to Anavex Life Sciences Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Anavex Life Sciences Corp News

Latest updates

Anavex Life Sciences Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-16.4%	472,000	564,667	657,333	750,000	824,188	898,376	972,564	1,046,752	1,120,940	1,195,128	1,269,316	4,519,444	1,319,913	717,328	943,215	738,684	552,335	760,990	413,682	-	1,629,513
Operating Expenses	-1.1%	12,519,000	12,652,167	13,530,697	14,189,159	15,384,000	15,284,143	11,723,390	12,252,584	11,398,655	8,954,586	9,396,175	-54,668,603	8,106,479	7,773,189	7,700,703	6,346,219	7,147,175	8,140,037	7,473,517	5,888,990	4,618,013
S&GA Expenses	-100.0%	-	2,591,571	3,247,843	2,882,568	3,317,000	3,902,440	3,066,951	2,879,472	2,434,127	2,233,745	1,470,656	1,402,955	1,381,477	1,720,142	1,352,035	1,635,312	1,388,729	2,061,251	1,761,307	1,481,538	1,620,379
R&D Expenses	-3.3%	9,729,000	10,060,596	10,282,854	11,306,591	12,067,000	11,381,703	8,656,439	9,373,112	8,964,528	6,720,841	7,925,519	6,104,906	6,725,002	6,053,047	6,348,668	4,710,907	5,758,446	6,078,786	5,712,210	4,407,452	2,997,634
EBITDA Margin	19.8%	-1.57	-1.95	-2.20	-2.32	-2.27	-2.22	-0.81	-0.48	-0.58	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-10.3%	1,756,000	1,958,025	1,827,945	1,465,221	1,268,000	704,595	4,910	6,890	11,453	9,216	-1,559	6,977	56,096	70,180	46,720	42,177	34,838	51,465	78,800	83,843	112,226
Income Taxes	264.1%	105,000	-63,977	41,000	50,000	-20,000	209,799	29,980	142,731	39,000	26,988	59,281	8,633	4,817	-	9,214	6,116	19,300	48,048	8,717	35,480	-
Earnings Before Taxes	-2.3%	-10,441,000	-10,209,863	-11,238,976	-13,057,279	-12,992,000	-14,080,682	-10,852,387	-11,575,841	-10,141,141	-8,128,234	-7,795,784	-5,956,593	-6,481,805	-7,236,697	-6,582,711	-5,600,302	-6,502,626	-7,198,856	-6,911,014	-5,556,903	-2,849,164
EBT Margin	14.9%	-1.93	-2.26	-2.45	-2.50	-2.37	-2.27	-0.81	-0.48	-0.58	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-3.9%	-10,546,000	-10,145,886	-11,279,976	-13,107,279	-12,972,000	-14,290,481	-10,882,367	-11,718,572	-10,180,141	-8,155,222	-7,855,065	-5,965,226	-6,486,622	-7,236,697	-6,591,925	-5,606,418	-6,521,926	-7,246,904	-6,919,731	-5,592,383	-2,849,164
Net Income Margin	14.5%	-1.93	-2.26	-2.46	-2.51	-2.39	-2.29	-0.82	-0.48	-0.58	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-99.3%	-11,656,000	-5,849,629	-7,652,535	-8,488,836	-5,794,000	-4,044,071	-3,500,955	-7,674,834	-7,520,943	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.4%	145	148	154	158	159	148	153	160	160	157	162	166	84.00	54.00	35.00	32.00	31.00	31.00	25.00	22.00	21.00
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	32.00	-	-	25.00	22.00	21.00
Cash Equivalents	-3.0%	139	144	151	155	153	144	149	153	153	151	152	158	76.00	47.00	29.00	28.00	27.00	27.00	22.00	21.00	19.00
Liabilities	-23.5%	10.00	12.00	13.00	11.00	14.00	13.00	10.00	-	-	-	11.00	9.00	9.00	8.00	7.00	7.00	6.00	6.00	5.00	-	-
Current Liabilities	-	-	-	-	-	-	-	-	9.00	8.00	11.00	11.00	-	8.00	8.00	7.00	7.00	6.00	5.00	5.00	4.00	6.00
Shareholder's Equity	-0.5%	135	136	142	147	145	135	142	151	152	146	151	157	76.00	46.00	27.00	25.00	25.00	26.00	20.00	21.00	17.00
Retained Earnings	-3.5%	-312	-301	-293	-282	-271	-258	-245	-231	-218	-208	-197	-185	-175	-167	-159	-153	-147	-139	-133	-131	-124
Additional Paid-In Capital	2.3%	447	437	435	430	417	394	388	382	371	355	348	343	251	214	187	178	172	166	154	149	139
Shares Outstanding	1.9%	84.00	82.00	82.00	81.00	80.00	78.00	78.00	78.00	77.00	76.00	70.00	75.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	667	-	-	-	921	-	-	-	1,012	-	-	-	177	-	-	-	140

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-59.3%	-11,656	-7,318	-5,849	-7,652	-8,488	-5,794	-4,044	-7,053	-9,639	-3,500	-7,674	-7,520	-7,316	-7,871	-6,254	-4,044	-5,262	-5,725	-2,534	-7,501	-4,331
Share Based Compensation	16.0%	2,652	2,286	3,187	3,867	3,970	5,347	6,042	3,989	4,439	3,909	3,152	2,294	1,846	939	661	1,251	1,701	1,264	1,237	1,234	1,893
Cashflow From Financing	12233.9%	7,277	59.00	2,056	9,003	18,334	258	2.00	6,910	11,836	2,540	2,223	89,222	35,819	25,980	7,885	5,100	4,368	10,998	3,471	9,293	3,074
Buy Backs	-	-	-	1,188	8,535	18,153	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AVXL Income Statement

2024-03-31

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
General and administrative	$ 2,790	$ 2,883	$ 5,399	$ 6,200
Research and development	9,729	11,307	18,413	23,373
Total operating expenses	12,519	14,190	23,812	29,573
Operating loss	(12,519)	(14,190)	(23,812)	(29,573)
Other income
Grant income	0	0	0	25
Research and development incentive income	472	750	1,064	1,483
Interest income, net	1,756	1,465	3,764	2,733
Other financing expense	0	(964)	0	(964)
Foreign exchange gain (loss)	(150)	(118)	7	247
Total other income, net	2,078	1,133	4,835	3,524
Net loss before provision for income taxes	(10,441)	(13,057)	(18,977)	(26,049)
Income tax expense, current	(105)	(50)	(191)	(30)
Net loss and comprehensive loss	$ (10,546)	$ (13,107)	$ (19,168)	$ (26,079)
Net Loss per share
Net Loss per share, Basic	$ (0.13)	$ (0.17)	$ (0.23)	$ (0.33)
Net Loss per share, Diluted	$ (0.13)	$ (0.17)	$ (0.23)	$ (0.33)
Weighted average number of shares outstanding
Weighted average number of shares outstanding, Basic	82,464,226	78,304,363	82,269,965	78,138,940
Weighted average number of shares outstanding, Diluted	82,464,226	78,304,363	82,269,965	78,138,940

AVXL Balance Sheet

2024-03-31

Condensed Consolidated Interim Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Sep. 30, 2023
Current
Cash and cash equivalents	$ 139,386	$ 151,024
Incentive and tax receivables	3,785	2,709
Prepaid expenses and other current assets	1,345	653
Total Assets	144,516	154,386
Current Liabilities
Accounts payable	3,726	4,322
Accrued liabilities - Note 4	4,915	7,295
Deferred grant income - Note 3	917	917
Total Liabilities	9,558	12,534
Commitments and Contingencies - Note 6
Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share	0	0
Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 82,086,511 common shares (September 30, 2023 - 82,066,511)	84	82
Additional paid-in capital	447,345	434,839
Share proceeds receivable	(234)	0
Accumulated deficit	(312,237)	(293,069)
Total Stockholders' Equity	134,958	141,852
Total Liabilities and Stockholders' Equity	$ 144,516	$ 154,386

About Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

CEO	Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
WEBSITE	anavex.com
INDUSTRY	Biotechnology
EMPLOYEES	38

Anavex Life Sciences Corp Frequently Asked Questions

What is the ticker symbol for Anavex Life Sciences Corp? What does AVXL stand for in stocks?

AVXL is the stock ticker symbol of Anavex Life Sciences Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Anavex Life Sciences Corp (AVXL)?

As of Fri May 17 2024, market cap of Anavex Life Sciences Corp is 385.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVXL stock?

You can check AVXL's fair value in chart for subscribers.

What is the fair value of AVXL stock?

You can check AVXL's fair value in chart for subscribers. The fair value of Anavex Life Sciences Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Anavex Life Sciences Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVXL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Anavex Life Sciences Corp a good stock to buy?

The fair value guage provides a quick view whether AVXL is over valued or under valued. Whether Anavex Life Sciences Corp is cheap or expensive depends on the assumptions which impact Anavex Life Sciences Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVXL.

What is Anavex Life Sciences Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AVXL's PE ratio (Price to Earnings) is -9.49 and Price to Sales (PS) ratio is 15.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVXL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Anavex Life Sciences Corp's stock?

In the past 10 years, Anavex Life Sciences Corp has provided 0.338 (multiply by 100 for percentage) rate of return.